Adam Pawinski
Overview
Explore the profile of Adam Pawinski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
321
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nieder C, Dalhaug A, Pawinski A
Anticancer Res
. 2020 Feb;
40(2):977-981.
PMID: 32014942
Background/aim: The aim of this study was to analyze the survival of patients with brain metastases treated with best supportive care or additional whole-brain radiotherapy (WBRT), in order to confirm...
2.
Nieder C, Dalhaug A, Pawinski A
J Clin Med Res
. 2019 Apr;
11(5):321-325.
PMID: 31019625
Background: The aim of this study was to validate the prognostic impact of the recently introduced three-tiered LabBM score in patients with brain metastases. In contrast to the previous development...
3.
Nieder C, Dalhaug A, Pawinski A
In Vivo
. 2019 Feb;
33(2):465-468.
PMID: 30804126
Background/aim: The aim of this study was to analyze the prognostic impact of biomarkers, such as serum lactate dehydrogenase (LDH), in patients with oligometastatic castration-resistant prostate cancer, arbitrarily defined as...
4.
Nieder C, Haukland E, Mannsaker B, Pawinski A, Yobuta R, Norum J
Anticancer Res
. 2018 Dec;
39(1):335-340.
PMID: 30591477
Background/aim: Compared to intravenous taxane chemotherapy, newer orally-available and/or less toxic agents for metastatic castration-resistant prostate cancer (MCRPC) may be associated with higher likelihood of starting treatment in patients with...
5.
Nieder C, Dalhaug A, Pawinski A
In Vivo
. 2018 Dec;
33(1):229-232.
PMID: 30587628
Background/aim: The aim of this study was to analyze the prognostic impact of serum lactate dehydrogenase (LDH) in patients with oligometastatic brain metastases, arbitrarily defined as max. Four brain lesions...
6.
Nieder C, Haukland E, Pawinski A, Norum J
Med Oncol
. 2018 Mar;
35(4):46.
PMID: 29508104
Recent research suggests that prostate-specific antigen (PSA) ≤ 0.2 ng/dl at 7 months is prognostic for better survival with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer regardless of chemotherapy...
7.
Nieder C, Kampe T, Pawinski A, Dalhaug A
Strahlenther Onkol
. 2018 Jan;
194(6):533-538.
PMID: 29344766
Background: Widely used prognostic scores, e. g., for brain or bone metastases, are based on disease- and patient-related factors such as extent of metastases, age and performance status, which were...
8.
Nieder C, Syed M, Dalhaug A, Pawinski A, Norum J
Med Oncol
. 2017 Jul;
34(9):149.
PMID: 28748331
Previous research has identified disparities between urban and rural cancer care, including clinical trial access. Therefore, we addressed three different questions in patients with metastatic renal cell cancer managed according...
9.
Nieder C, Mannsaker B, Dalhaug A, Pawinski A, Haukland E
Mol Clin Oncol
. 2017 Jun;
6(6):811-816.
PMID: 28588769
The purpose of the present retrospective study was to investigate whether a score reflecting systemic inflammatory processes [the Glasgow Prognostic Score (GPS)] provides relevant information for radiation oncologists. GPS is...
10.
Nieder C, Tollali T, Yobuta R, Reigstad A, Randi Flatoy L, Pawinski A
J Clin Med Res
. 2017 May;
9(6):482-487.
PMID: 28496548
Background: Effective symptom palliation can be achieved with low-dose palliative thoracic radiotherapy. In several studies, median survival was not improved with higher doses of radiation. More controversy exists regarding the...